Publications du CNR en 2021

Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, Typhaine, Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N., Robert, J., Bouchaud, O., Billard-Pomares, T., Carbonnelle, E., Mechaï, F., Nunes, H., Pellan, M., Morin, A.-S., Dumesnil, C., Dumoulin, J., Roux, A.-L., Jachym, M., le Du, D., Marigot-Outtandy, D., Abgrall, S., Chambrin, V., Guillet, C., Fantin, B., Galy, A., Decousser, J.-W., Lelièvre, J. D., Gallien, S., Nebbad-Lechani, B., Deconinck, L., Bulifon, S., Fortineau, N., Wyplosz, B., Cohen, F., Lemaitre, N., Crestani, B., Grall, N., Pierre-Audigier, C., Rioux, C., Yazdanpanah, Y., Le Jeunne, C., Morand, P., Roche, N., Pavie, J., Loulergue, P., Delcey, V., Lecorché, E., Munier, A.-L., Mougari, F., Sellier, P., Bille, E., Ferroni, A., Guéry, R., Hummel, A., Lourenco, J., Aubry, A., Bonnet, I., Caumes, E., Londner, C., Morel, F., Lacombe, K., Lalande, V., Meynard, J.-L., Veziris, N., De Castro, N., Denis, B., Lafaurie, M., Molina, J.-M., Canestri, A., Lassel, L., Pialoux, G., Verdet, C., Nardi, A.-L., Gominet, M. and Catherinot, E. (2021). Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases 107, 86–91, http://doi.org/10.1016/j.ijid.2021.03.093.

Bemer, P., Peuchant, O., Guet-Revillet, H., Bador, J., Balavoine, C., Basille, D., Beltramo, G., Blanc, F.-X., Blanchard, E., Boulanger, S., Bourgoin, A., Boutoille, D., Cambau, E., Canis, F., Caparros, D., Carricajo, A., Carrière, C., Couetdic, G., Couturaud, F., Dalphin, J.-C., Degot, T., Desquiens, M., Devouassoux, G., Duez, J.-M., Dumitrescu, O., Dupuy-Grasset, M., Gaudart, A., Georges, M., Godet, C., Godreuil, S., Guillouzouic, A., Hamdad-Daoudi, F., Héry-Arnaud, G., Koebel, C., Lagrange, A., Lanotte, P., Marchand-Adam, S., Mougari, F., Murris, M., Patry, I., Pérouse de Montclos, M., Raskine, L., Risso, K., Segonds, C., Sicard, D., Terru, D., Vachée, A., Vergnon, J.-M., Martin, C., Schramm, F. and Andrejak, C. (2021). Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study. BMC Pulm Med 21, 1–9, http://doi.org/10.1186/s12890-021-01701-5.

Bonnet, I., Enouf, V., Morel, F., Ok, V., Jaffré, J., Jarlier, V., Aubry, A., Robert, J. and Sougakoff, W. (2021). A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 11, 707244, http://doi.org/10.3389/fcimb.2021.707244.

Calin, R., Belkacem, A., Caraux-Paz, P., Wagner, M., Guillot, H., Veziris, N., Jaureguiberry, S., Caumes, E., Patey, O. and Pourcher, V. (2021). Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region. The American Journal of Tropical Medicine and Hygiene 104, 223–228, http://doi.org/10.4269/ajtmh.20-0023.

Chauffour, A., Morel, F., Reibel, F., Petrella, S., Mayer, C., Cambau, E. and Aubry, A. (2021). A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clinical Microbiology and Infection 27, 1601–1612, http://doi.org/10.1016/j.cmi.2021.07.007.

Gies, V., Dieudonné, Y., Morel, F., Sougakoff, W., Carapito, R., Martin, A., Weingertner, N., Jacquel, L., Hubele, F., Kuhnert, C., Jung, S., Schramm, F., Boyer, P., Hansmann, Y., Danion, F., Korganow, A.-S. and Guffroy, A. (2021). Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy. Front Immunol 12, 696268, http://doi.org/10.3389/fimmu.2021.696268.

Guglielmetti, L. and Varaine, F. (2021). The coming-of-age of bedaquiline: a tale with an open ending. European Respiratory Journal 57, http://doi.org/10.1183/13993003.00066-2021.

Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. D. S., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F. and Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials 22, 651, http://doi.org/10.1186/s13063-021-05491-3.

Hewison, C. and Guglielmetti, L. (2021). Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. Lancet Infect Dis 21, 894–895, http://doi.org/10.1016/S1473-3099(20)30836-7.

Lecorche, E., Daniau, C., La, K., Mougari, F., Benmansour, H., Kumanski, S., Robert, J., Fournier, S., Lebreton, G., Carbonne, A., Cambau, E. and CNR-MyRMA (2021). Mycobacterium chimaera Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical Mycobacterium chimaera Infection Outbreak. Open Forum Infectious Diseases 8, ofab192, http://doi.org/10.1093/ofid/ofab192.

Maitre, T., Guglielmetti, L. and Veziris, N. (2021). Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal 57, http://doi.org/10.1183/13993003.04315-2020.

Maitre, T., Ok, V., Morel, F., Bonnet, I., Sougakoff, W., Robert, J., Trosini, V., Caumes, E., Aubry, A. and Veziris, N. (2021). Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research 79, 100825, http://doi.org/10.1016/j.resmer.2021.100825.

Mohamed, S., Köser, C. U., Salfinger, M., Sougakoff, W. and Heysell, S. K. (2021). Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics? European Respiratory Journal 57, http://doi.org/10.1183/13993003.04077-2020.

Molina‐Moya, B., Guglielmetti, L., Bothamley, G., van Leth, F., Lange, C., Dominguez, J. and TBnet Study Group (2021). Use and impact of molecular methods for detecting drug‐resistant TB. The International Journal of Tuberculosis and Lung Disease 25, 157–159, http://doi.org/10.5588/ijtld.20.0527.

Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D. and Guglielmetti, L. (2021). TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 22, 1–3, http://doi.org/10.1186/s13063-021-05331-4.

Ok, V., Aubry, A., Morel, F., Bonnet, I., Robert, J. and Sougakoff, W. (2021). Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics 10, 797, http://doi.org/10.3390/antibiotics10070797.

Opota, O., Mazza-Stalder, J., Viveiros, M., Cambau, E., Santin, M. and Goletti, D. (2021). Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. Frontiers in Public Health 9, URL: https://www.frontiersin.org/article/10.3389/fpubh.2021.666187 [Accessed March 2022].

Ortuño-Gutiérrez, N., Mzembaba, A., Ramboarina, S., Andriamira, R., Baco, A., Braet, S., Younoussa, A., Cauchoix, B., Salim, Z., Amidy, M., Grillone, S., Rasamoelina, T., Cambau, E., Geluk, A., de Jong, B. C., Richardus, J. H. and Hasker, E. (2021). Exploring clustering of leprosy in the Comoros and Madagascar: A geospatial analysis. International Journal of Infectious Diseases 108, 96–101, http://doi.org/10.1016/j.ijid.2021.05.014.

Roelens, M., Battista Migliori, G., Rozanova, L., Estill, J., Campbell, J. R., Cegielski, J. P., Tiberi, S., Palmero, D., Fox, G. J., Guglielmetti, L., Sotgiu, G., Brust, J. C. M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O. and Raviglione, M. (2021). Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 204, 713–722, http://doi.org/10.1164/rccm.202009-3527OC.

Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2021). Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection 27, 288.e1-288.e4, http://doi.org/10.1016/j.cmi.2020.10.019.

Starshinova, A., Guglielmetti, L., Rzhepishevska, O., Ekaterincheva, O., Zinchenko, Yu. and Kudlay, D. (2021). Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). J Clin Tuberc Other Mycobact Dis 24, 100259, http://doi.org/10.1016/j.jctube.2021.100259.

Tagliani, E., Anthony, R., Kohl, T. A., de Neeling, A., Nikolayevskyy, V., Ködmön, C., Maurer, F. P., Niemann, S., van Soolingen, D., van der Werf, M. J. and Cirillo, D. M. (2021). Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017–2019: an ECDC pilot study. Eur Respir J 57, 2002272, http://doi.org/10.1183/13993003.02272-2020.

Veziris, N., Andréjak, C., Bouée, S., Emery, C., Obradovic, M. and Chiron, R. (2021). Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study. BMC Infect Dis 21, 1–10, http://doi.org/10.1186/s12879-021-06825-x.

Veziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J. and Aubry, A. (2021). Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal 58, http://doi.org/10.1183/13993003.00641-2021.

World Health Organisation (2021). Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), WHO, Geneva, URL: https://www.who.int/publications/i/item/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine) [Accessed March 2022].